Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$82.85
+0.1%		$84.30
$28.12
▼
$95.49
$11.67B1.281.20 million shs1.34 million shs
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$107.20
+0.2%		$93.73
$61.22
▼
$111.15
$12.14B0.881.56 million shs861,533 shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$534.49
+0.3%		$530.99
$393.61
▼
$615.00
$12.32B-0.98213,239 shs187,642 shs
uniQure N.V. stock logo
QURE
uniQure
$44.51
+0.1%		$44.36
$8.73
▼
$71.50
$3.08B0.941.10 million shs1.24 million shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
+0.11%-4.04%-5.04%+11.18%+186.78%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
+0.19%-2.71%+5.31%+54.24%+41.42%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
+0.26%-1.22%-0.32%+11.17%+24.27%
uniQure N.V. stock logo
QURE
uniQure
+0.09%+0.02%-1.37%+61.44%+154.63%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$82.85
+0.1%		$84.30
$28.12
▼
$95.49
$11.67B1.281.20 million shs1.34 million shs
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$107.20
+0.2%		$93.73
$61.22
▼
$111.15
$12.14B0.881.56 million shs861,533 shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$534.49
+0.3%		$530.99
$393.61
▼
$615.00
$12.32B-0.98213,239 shs187,642 shs
uniQure N.V. stock logo
QURE
uniQure
$44.51
+0.1%		$44.36
$8.73
▼
$71.50
$3.08B0.941.10 million shs1.24 million shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
+0.11%-4.04%-5.04%+11.18%+186.78%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
+0.19%-2.71%+5.31%+54.24%+41.42%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
+0.26%-1.22%-0.32%+11.17%+24.27%
uniQure N.V. stock logo
QURE
uniQure
+0.09%+0.02%-1.37%+61.44%+154.63%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
2.64
Moderate Buy$99.1519.68% Upside
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
2.62
Moderate Buy$91.20-14.93% Downside
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
2.78
Moderate Buy$699.6430.90% Upside
uniQure N.V. stock logo
QURE
uniQure
2.76
Moderate Buy$65.0046.03% Upside

Current Analyst Ratings Breakdown

Latest QURE, MDGL, HALO, and ARWR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/8/2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$108.00
9/2/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$115.00
9/2/2026
uniQure N.V. stock logo
QURE
uniQure
William Blair logo
William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageHold ➝ Outperform
9/1/2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$120.00
8/31/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeBuy (B-) ➝ Buy (B)
8/31/2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$100.00
8/31/2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
Chardan Capital logo
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$115.00
8/17/2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
8/14/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy (B) ➝ Buy (B-)
8/7/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform
8/7/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$96.00 ➝ $105.00
(Data available from 9/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$669.50M17.43$0.12 per share693.13$3.64 per share22.76
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$1.40B8.71$4.78 per share22.43$0.42 per share255.24
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$958.40M12.88N/AN/A$26.54 per share20.14
uniQure N.V. stock logo
QURE
uniQure
$16.10M191.78N/AN/A$3.19 per share13.95
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-$1.63M-$2.25N/AN/AN/A-47.79%-60.06%-17.37%11/24/2026 (Estimated)
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$316.89M$3.3532.0011.490.4124.86%260.98%23.91%11/2/2026 (Estimated)
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$288.28M-$12.89N/A96.30N/A-25.32%-56.65%-25.53%11/3/2026 (Estimated)
uniQure N.V. stock logo
QURE
uniQure
-$198.97M-$4.01N/AN/AN/A-1,350.73%-111.96%-29.01%11/9/2026 (Estimated)

Latest QURE, MDGL, HALO, and ARWR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$1.79$2.28+$0.49$1.90$402.28 million$481.00 million
8/4/2026Q3 2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-$1.23-$1.36-$0.13-$1.36$44.17 million$75.25 million
7/30/2026Q2 2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$2.68-$1.99+$0.69-$1.99$352.13 million$364.25 million
7/29/2026Q2 2026
uniQure N.V. stock logo
QURE
uniQure
-$0.8223-$1.22-$0.3977-$1.22$5.45 million$5.84 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
N/AN/AN/AN/AN/A
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
N/AN/AN/AN/AN/A
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
N/AN/AN/AN/AN/A
uniQure N.V. stock logo
QURE
uniQure
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
1.77
5.90
5.90
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
13.50
2.71
2.31
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.65
3.20
2.94
uniQure N.V. stock logo
QURE
uniQure
0.15
10.01
10.01

Institutional Ownership

CompanyInstitutional Ownership
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
62.61%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
97.79%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
98.50%
uniQure N.V. stock logo
QURE
uniQure
78.83%

Insider Ownership

CompanyInsider Ownership
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
3.60%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
2.50%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
17.60%
uniQure N.V. stock logo
QURE
uniQure
4.65%
CompanyEmployeesShares OutstandingFree FloatOptionable
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
711140.86 million135.79 millionOptionable
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
423113.50 million110.66 millionOptionable
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
91523.10 million19.04 millionOptionable
uniQure N.V. stock logo
QURE
uniQure
22169.37 million66.14 millionOptionable

Recent News About These Companies

FDA expands Bayer lung cancer drug approval
September 10 at 2:32 PM  |  statnews.comS
What to expect from UniQure’s upcoming Huntington’s gene therapy readout
September 10 at 2:32 PM  |  statnews.comS
Squarepoint Ops LLC Has $12.91 Million Stock Holdings in uniQure N.V. $QURE
September 10 at 5:21 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-squarepoint-ops-llc-has-1291-million-stock-holdings-in-uniqure-nv-qure-2026-09-10/
uniQure (QURE) Submitted AMT-130 for Accelerated Approval in Huntington’s Disease. Can Externally Controlled Data Support the Application?
September 8, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/uniqure-qure-submitted-amt-130-for-accelerated-approval-in-huntingtons-disease-can-externally-controlled-data-support-the-application-1826782/
uniQure N.V. $QURE Shares Sold by Readystate Asset Management LP
September 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-uniqure-nv-qure-shares-sold-by-readystate-asset-management-lp-2026-09-07/
QURE stock gains as uniQure moves closer to FDA review for Huntington’s gene therapy
September 6, 2026  |  ad-hoc-news.deA
QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now
September 5, 2026  |  investorplace.comhttps://investorplace.com/dailylive/2026/06/qure-was-just-the-beginning-5-biotech-catalysts-to-watch/?utm_source=atom&utm_medium=test
Wall Street Zen Downgrades uniQure (NASDAQ:QURE) to Sell
September 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31003828
uniQure (NASDAQ:QURE) Lowered to Sell Rating by Wall Street Zen
September 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-uniqure-nasdaq-qure-lowered-to-sell-rating-by-wall-street-zen-2026-09-05/
uniQure submits ifezuntirgene inilparvovec BLA to US FDA to treat Huntington’s disease
September 4, 2026  |  pharmabiz.comP
uniQure (NASDAQ:QURE) Shares Gap Up - Here's Why
September 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31003234
uniQure (NASDAQ:QURE) Coverage Initiated at William Blair
September 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31001852
uniQure files for US and UK approval for AMT-130 in Huntington’s disease
September 3, 2026  |  thepharmaletter.comT
uniQure (NASDAQ:QURE) Trading Down 4.4% - Here's Why
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-uniqure-nasdaq-qure-trading-down-44-heres-why-2026-09-03/
QURE Submits Application for Gene Therapy for Huntington's Disease
September 3, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2984452/qure-submits-application-for-gene-therapy-for-huntington-s-disease?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2984452
QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now
September 3, 2026  |  investorplace.comhttps://investorplace.com/dailylive/2026/06/qure-was-just-the-beginning-5-biotech-catalysts-to-watch/?utm_source=barchart&utm_medium=hotstocks
UniQure, after setbacks, seeks FDA approval of Huntington’s gene therapy
September 2, 2026  |  biopharmadive.comB
UniQure Submits Biologics License Application For AMT-130 In Huntington's Disease; Stock Up
September 2, 2026  |  rttnews.comhttps://www.rttnews.com/3687825/uniqure-submits-biologics-license-application-for-amt-130-in-huntington-s-disease-stock-up.aspx
Pharmalittle: We’re reading about a Huntington’s gene therapy, Novo’s challenges, and more
September 2, 2026  |  statnews.comS
uniQure Submits BLA for AMT-130 in Huntington's Disease
September 2, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/uniqure-submits-bla-amt-130-114130260.html
uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease
September 2, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/uniqure-announces-submission-of-biologics-license-application-for-ifezuntirgene-inilparvovec-amt-130-in-huntington-s-disease-1036514962

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
A quantum computing processor glows inside a gold-plated dilution refrigerator in a research laboratory.
The Quantum Race Is Heating Up—And 2 Small Players Stand Out
By Nathan Reiff | August 17, 2026
NVIDIA logo over a computer chip, server racks, and an upward-trending green stock price chart.
NVIDIA’s Blockbuster Quarter May Still Undersell How Big the AI Buildout Is
By Thomas Hughes | August 27, 2026
Illustration of a computer chip on a circuit board with an upward green stock chart line in a server room.
Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
By Thomas Hughes | August 31, 2026
Illustration of an upward-trending stock chart line overlaid on a city skyline of office towers at sunset.
Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally
By Nathan Reiff | August 30, 2026
An AV-branded unmanned helicopter drone sits on rocky desert terrain with mountains at sunset.
AeroVironment Hit a Bottom in Q2—Can It Take Flight in Q3?
By Thomas Hughes | August 19, 2026
Arrowhead Pharmaceuticals stock logo

Arrowhead Pharmaceuticals NASDAQ:ARWR

$82.85 +0.09 (+0.11%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$82.50 -0.35 (-0.42%)
As of 09/11/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Halozyme Therapeutics stock logo

Halozyme Therapeutics NASDAQ:HALO

$107.20 +0.20 (+0.19%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$106.32 -0.88 (-0.82%)
As of 09/11/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Madrigal Pharmaceuticals stock logo

Madrigal Pharmaceuticals NASDAQ:MDGL

$534.49 +1.37 (+0.26%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$534.42 -0.07 (-0.01%)
As of 09/11/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

uniQure stock logo

uniQure NASDAQ:QURE

$44.51 +0.04 (+0.09%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$44.60 +0.09 (+0.20%)
As of 09/11/2026 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas